BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Adebrelimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Adebrelimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06685653-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06685653)
DESCRIPTION:Adebrelimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Per
 sonalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small C
 ell Lung Cancer Patients\nEstimated primary completion: 30 November 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06685653
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770113-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07770113)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Random\, Non-controlled\, Open
  Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxe
 l ± Adebrelimab in Treating Advanced Second-line Gastric Cancer\nEstimate
 d primary completion: 30 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07770113
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06735508-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06735508)
DESCRIPTION:Adebrelimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: MRN
 A Neoantigen Vaccine in Non-Small Cell Lung Cancer\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06735508
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 i
 n Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05482568
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Clinical Study of SHR-A1811 
 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06840002
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06454578-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06454578)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adjuvant Adebrelimab Plus Apatin
 ib for Participants With HCC at High-risk of Recurrence After Curative Res
 ection\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06454578
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749730-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06749730)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined with Apatin
 ib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectabl
 e Biliary Tract Carcinoma\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06749730
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915142-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06915142)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Phase II Clinical Study of HRS
 -7058 in Combination With Antitumor Drugs in Patients With Advanced Malign
 ant Tumour\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06915142
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844474-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06844474)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844474
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035392-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07035392)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC\nEstim
 ated primary completion: 1 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07035392
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483282-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06483282)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoad
 juvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Can
 cer\nEstimated primary completion: 1 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06483282
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267234-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07267234)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: PRaG-1 Plus PRaG Therapy in in E
 lderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (
 PRaG 10.0)\nEstimated primary completion: 1 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07267234
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062328-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07062328)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Trial of Recaticimab and Adebr
 elimab in Combination With Chemotherapy in Patients With Unresectable BTC\
 nEstimated primary completion: 10 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07062328
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699576-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06699576)
DESCRIPTION:Adebrelimab\, phase 1.\nStudy: ARTEMIS-103: Phase 1b Study of H
 S-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06699576
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141264-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07141264)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07141264
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465563-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06465563)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: SHR-8068 in Combination With Ade
 brelimab\, Bevacizumab\, and Platinum-Based Chemotherapy as First-line Tre
 atment in Patients With Advanced Biliary Tract Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06465563
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06199271-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06199271)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Adebrelimab Plus Dal
 piciclib in Head and Neck Squamous Cell Carcinoma\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06199271
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531278-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06531278)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebelimab Combined With Irinote
 can Liposomal Injection\, Oxaliplatin\, Fluorouracil and Calcium Folinate 
 Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis
  Efficacy and Safety\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06531278
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620848-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06620848)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Study of HRS-4642 Monotherapy 
 or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tr
 act Tumors.\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06620848
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819319-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06819319)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: SHR-A2102 Combined With Adebreli
 mab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06819319
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06808971-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06808971)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Nab-pa
 clitaxel\, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Lo
 cally Advanced Resectable GC/GEJ\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06808
 971
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076682-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT05076682)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Reverse Triple Negative Immune R
 esistant Breast Cancer\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05076682
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091124-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06091124)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Adebrelimab Plus Eto
 poside and Cisplatin in Neuroendocrine Bladder Carcinoma\nEstimated primar
 y completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06091124
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136142-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07136142)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Phase I/II Clinical Study of
  FH-006 for Injection in Patients With Malignant Solid Tumors\nEstimated p
 rimary completion: February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07136142
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031154-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07031154)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 ingle-arm\, Multicenter\, Prospective Clinical Study of Adebrelimab Combin
 ed With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Ca
 ncer\nEstimated primary completion: 1 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07031154
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452601-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07452601)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Time-of-Day of Immunotherapy Inf
 usion in Neoadjuvant Immunochemotherapy for Thoracic ESCC\nEstimated prima
 ry completion: 25 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07452601
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388095-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Adebrelimab: Phase na readout est. (NCT07388095)
DESCRIPTION:Adebrelimab\, phase na.\nStudy: Adebrelimab Neoadjuvant Treatme
 nt for Resectable ESCC\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07388095
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059221-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07059221)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Trial of SHR-A2102 With Adeb
 relimab With or Without Other Anti-tumor Therapies in Recurrent/Metastatic
 Head and Neck Squamous Cell Carcinoma Cancer\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrel
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07059221
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861894-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06861894)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Active Surveillance After Neoadj
 uvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC\nEst
 imated primary completion: March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06861894
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547736-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06547736)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Exploratory Platform Research on
  Precision Therapy of Advanced Pancreatic Cancer\nEstimated primary comple
 tion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ade
 brelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06547736
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Study of ADCs Combined With Adeb
 relimab in HER2-negative Advanced Breast Cancer\nEstimated primary complet
 ion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adeb
 relimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06433609
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06296563-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06296563)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Perioperative Treatment of Resec
 table Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab 
 and Apatinib and HAIC\nEstimated primary completion: 1 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06296563
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684158-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06684158)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Mecapegfilgrastim Combined With 
 Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC\
 nEstimated primary completion: 1 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06684158
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06306560-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06306560)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment 
 of ES-SCLC.\nEstimated primary completion: 15 March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06306560
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280508-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06280508)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Chemotherapy Combined With Adebr
 elimab and Apatinib as the Perioperative Treatment in Patients With Biliar
 y Tract Cancer\nEstimated primary completion: 31 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06280508
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Anti-PD-1/PD-L1 Combined With An
 ti-angiogenic Agents as First-line Treatment for Unresectable HCC\nEstimat
 ed primary completion: 31 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06648525-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06648525)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined with Irinot
 ecan Liposomes\, 5-FU\, CF ± Lenvatinib As First-line Treatment for Advan
 ced ICC\nEstimated primary completion: April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06648525
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332950-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06332950)
DESCRIPTION:Adebrelimab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Withou
 t Famitinib in ES-SCLC Pre-treated With Immunotherapy\nEstimated primary c
 ompletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06332950
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537505-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06537505)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Study of Microwave Ablation Co
 mbined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Sol
 id Tumors\nEstimated primary completion: 1 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06537505
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704177-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07704177)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Phase II Study of Trastuzumab Re
 zetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive
 /Low-Expression Biliary Tract Cancer\nEstimated primary completion: 15 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0770
 4177
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670273-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07670273)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Phase II Study of Trastuzumab Re
 zetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for
  Advanced HER2-Positive/HER2-Low Biliary Tract Cancer\nEstimated primary c
 ompletion: 29 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07670273
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943235-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06943235)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study o
 f Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy 
 and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small 
 Cell Lung Cancer (LS-SCLC)\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06943235
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389500-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06389500)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: HAIC+Adebrelimab+Lenvatinib for 
 Conversion Treatment of Potentially Resectable\, Locally Advanced Biliary 
 Tract Cancer\nEstimated primary completion: 1 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06389500
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06385873)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: RC48 Combined With Adebrelimab\,
  Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cance
 r\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424899-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06424899)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafte
 r Compared With Immunoconsolidation After Radical Chemoradiotherapy for St
 age III Potentially Resectable NSCLC\nEstimated primary completion: 19 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064248
 99
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508229-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06508229)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Albumi
 n Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Re
 sectable ESCC\nEstimated primary completion: 30 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06508229
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639347-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06639347)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Trial of SHR-A2102 With Anti
 tumor Therapy in Advanced Urothelial Carcinoma\nEstimated primary completi
 on: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adeb
 relimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06639347
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105592-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07105592)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Study of Nimotuzumab Plus Ad
 ebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And
  Neck Squamous Cell Carcinoma\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07105592
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427239-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06427239)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Exploratory Clinical Study of 
 HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic
  Ductal Adenocarcinoma\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06427239
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192848-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07192848)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab + Apatinib in Advanc
 ed HCC Post-Systemic Therapy\nEstimated primary completion: June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07192848
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131514-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07131514)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: HRS-4642 in Combination With Gem
 citabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and 
 Adjuvant Treatment of Pancreatic Cancer\nEstimated primary completion: Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07131
 514
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06985602-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06985602)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab With Chemoradiothera
 py and Surgery for G/GEJ\nEstimated primary completion: 1 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06985602
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925516-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06925516)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Trial of Apatinib and Adebreli
 mab in Combination With Chemotherapy in Patients With Unresectable ICC\nEs
 timated primary completion: 1 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06925516
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778732-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07778732)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Dalpic
 iclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally A
 dvanced Head and Neck Squamous Cell Carcinoma\nEstimated primary completio
 n: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebr
 elimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07778732
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480136-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06480136)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Fa
 iled the Previous Standard First-line Treatment\nEstimated primary complet
 ion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06480136
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135544-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07135544)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Single-arm\, Multicenter\, Exp
 loratory Study of Adebrelimab Combined With Apatinib and Systemic Chemothe
 rapy for Initially Unresectable Biliary Tract Cancer\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07135544
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137858-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07137858)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Carbop
 latin and Albumin-bound Taxanol in the Treatment of Resectable Locally Adv
 anced Oral Squamous Cell Carcinoma Cardiac\, Randomized\, Phase II Explora
 tory Study\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07137858
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230301-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07230301)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Infusion Plus Standa
 rd Care for Pancreatic Cancer With Pleural or Peritoneal Effusions\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07230301
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668453-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07668453)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: An Open-label\, Single-arm\, Mul
 ticenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Al
 bumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignanc
 ies\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07668453
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430579-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adebrelimab: Phase na readout est. (NCT07430579)
DESCRIPTION:Adebrelimab\, phase na.\nStudy: Adebrelimab Combined With Chemo
 therapy for the Esophageal Squamous Cell Carcinoma\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07430579
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682272-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07682272)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Trial of SHR-8068 Combined Wit
 h Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepato
 cellular Carcinoma\nEstimated primary completion: July 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07682272
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786312-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270725
DTEND;VALUE=DATE:20270726
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06786312)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Singl
 e-arm\, Multicenter\, Prospective Phase II Clinical Study of Apatinib in C
 ombination With Adebrelimab and EC Regimen in the First-line Treatment of 
 Extensive Small Cell Lung Cancer\nEstimated primary completion: 25 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06786312
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562920-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06562920)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatm
 ent of Limited-stage Small Cell Lung Cancer\nEstimated primary completion:
  31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebre
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06562920
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309185-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07309185)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Famiti
 nib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line 
 Therapy\nEstimated primary completion: 31 July 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07309185
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05496166-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT05496166)
DESCRIPTION:Adebrelimab\, phase 3\, Small Cell Lung Cancer.\nStudy: The Eff
 iciency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Plati
 num-containing Doublet Induction Therapy for Limited-stage Small Cell Lung
  Cancer\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05496166
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137039-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07137039)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Treatment of Locally
  Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemothe
 rapy Regimen\nEstimated primary completion: 20 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07137039
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778745-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07778745)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective Phase II Clinical Trial Evaluating the Efficacy and Safety of A
 debrelimab in Combination With Trastuzumab Rezetecan for Patients With Sta
 ge III Unresectable HER2-Positive NSCLC\nEstimated primary completion: 30 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebreli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07778745
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009457-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT07009457)
DESCRIPTION:Adebrelimab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Clini
 cal Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as Firs
 t-line Treatment for Extensive Stage Small Cell Lung Cancer\nEstimated pri
 mary completion: September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07009457
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909863-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07909863)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Low-Dos
 e Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small
  Cell Lung Cancer\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07909863
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06766019-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06766019)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Irinot
 ecan Liposomal (II)\, Oxaliplatin\, and 5-FU/LV Conversion Therapy for Loc
 ally Advanced Pancreatic Cancer\nEstimated primary completion: 30 Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06766
 019
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296341-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07296341)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: HRS-4642 Combination With Othe
 r Antitumor Therapies in Patients With Solid Tumors\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07296341
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691593-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07691593)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant HRS-4642 Plus Chemot
 herapy With or Without Immunotherapy for Pancreatic Cancer\nEstimated prim
 ary completion: October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07691593
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890701-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07890701)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Single-Arm\,Multicenter Phas
 e\, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the
  Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Childr
 en and Adolescents\nEstimated primary completion: 1 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07890701
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583550-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07583550)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Low-dos
 e Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy\, and Th
 en Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Sma
 ll Cell Lung Cancer\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07583550
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241767-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07241767)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Phase II Clinical Study of FH-
 006 for Injection Combined With Other Anticancer Therapies in Subjects Wit
 h Lung Cancer\nEstimated primary completion: November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07241767
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754930-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06754930)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SHR-1826 for Injection in Combination With Other Antitumor Thera
 pies in Subjects With NSCLC\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06754930
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229586-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07229586)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Study of SHR-7367 With Anti-
 tumor Agents in Patients With Solid Tumors\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebre
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07229586
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073534-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07073534)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Phase I/II Clinical Study of S
 HR-1501 Combined With Adbelizumab in Patients With Malignant Tumors\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07073534
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281209-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07281209)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Re
 sectable HER2-Altered Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07281209
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Ph1b/2 Study of the Safety and E
 fficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Canc
 er\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751341-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07751341)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Clinical Study of SHR-9839 as 
 Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Ch
 emotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous 
 Cell Carcinoma\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07751341
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510660-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06510660)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab ±Induction Chemothe
 rapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Adv
 anced ESCC\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06510660
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614621-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06614621)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequen
 tial Treatment for Extensive-stage Small Cell Lung Cancer\nEstimated prima
 ry completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06614621
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06916975-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06916975)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With AG Reg
 imen in Patients With Unresectable Locally Advanced or Metastatic Pancreat
 ic Cancer\nEstimated primary completion: 1 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06916975
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893887-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Adebrelimab: Phase na readout est. (NCT06893887)
DESCRIPTION:Adebrelimab\, phase na.\nStudy: Individualized Comprehensive Tr
 eatment for Advanced Hepatocellular Carcinoma\nEstimated primary completio
 n: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06893887
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350006-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06350006)
DESCRIPTION:Adebrelimab\, phase 1.\nStudy: SHR-A1904 Combinations in CLDN18
 .2-Positive Advanced Solid Tumor\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350
 006
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177522-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06177522)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Chemot
 herapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer\nEstimated 
 primary completion: 30 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06177522
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 debrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764368-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06764368)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Phase II Study of Adebrelimab\, 
 Chemotherapy\, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06764368
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869213-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06869213)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Single-arm\, Open\, Single-cen
 ter Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemot
 herapy for the Perioperative Treatment of Locally Advanced Resectable Esop
 hageal Squamous Carcinoma\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06869213
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584031-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07584031)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Plus Full-course Neo
 adjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07584031
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Fudan University Shanghai Cancer
  Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718490-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07718490)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Immunotheray Combined With Simva
 statin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07718490
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733830-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07733830)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Comparing ICI Followed By CCRT A
 nd CCRT Followed By Immunotherapy In Unresectable LA-ESCC\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07733830
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561775-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07561775)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Plus S-1 for Resecte
 d Cholangiocarcinoma\nEstimated primary completion: 1 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07561775
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595770-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07595770)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Neoadj
 uvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma\nEstimated 
 primary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07595770
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638436-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07638436)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Neoadj
 uvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Sq
 uamous Cell Carcinoma\nEstimated primary completion: 1 January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07638436
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Study of Multi-mode Thermal Ther
 apy Combined With Immunotherapy In Patients With HER2-negative Breast Canc
 er With Liver Metastases\nEstimated primary completion: 15 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392541-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07392541)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Adebrelimab Combined With Gemc
 itabine\, Cisplatin\, and Simvastatin for Advanced Biliary Tract Cancer\nE
 stimated primary completion: 30 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07392541
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Trial of SHR-A2102 With Adebre
 limab in Locally Advanced or Metastatic Urothelial Carcinoma\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149767-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06149767)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Clinical Study of Adebrelimab Co
 mbined With Concurrent Chemoradiotherapy in Cervical Cancer\nEstimated pri
 mary completion: February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06149767
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398560-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07398560)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combined With Oral Etoposide for Elderly Patients and Patients With P
 oor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical 
 Study\nEstimated primary completion: 1 February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07398560
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353684-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07353684)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Plus Apatinib Combin
 ed With SOX Regimen as Conversion Therapy for Gastric Cancer\nEstimated pr
 imary completion: 1 February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07353684
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791460-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06791460)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: Pegylated Liposomal Doxorubici
 n Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer\n
 Estimated primary completion: 14 February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06791460
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Clinical Trial of SHR-A1811 in
  the Treatment of Triple-negative Breast Cancer\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adeb
 relimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07111832
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479628-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07479628)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Adebrelimab Plus CRT
  for Locally Advanced Thymic Carcinoma\nEstimated primary completion: 1 Ma
 rch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 79628
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339619-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06339619)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Combination Immunotherapy of Ade
 brelimab With Apatinib and Tegafur\, Gimeracil and Oteracil Potassium Caps
 ules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma\
 nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06339619
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200154-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07200154)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited
 -Stage SCLC\nEstimated primary completion: 30 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07200154
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20
 093 Injection in Previously Treated Patients With Advanced or Metastatic N
 on-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterati
 ons\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168200-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07168200)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Clinical Study of Ad
 ebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combin
 ed With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced
  Cervical Cancer\nEstimated primary completion: April 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07168200
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349889-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06349889)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab and Chemoradiotherap
 y in High-risk LANPC\nEstimated primary completion: 1 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06349889
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687433-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07687433)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Long-Course Concurrent Chemoradi
 otherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally 
 Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation\nEstimat
 ed primary completion: 29 May 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07687433
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06778031-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06778031)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Clinical Study of SHR-A1811 in
  the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tra
 ct Cancer\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06778031
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704645-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07704645)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a 
 Treatment for Resectable Non-small Cell Lung Cancer\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 debrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07704645
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638852-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07638852)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Study of Radiotherapy Combined W
 ith Cisplatin/Carboplatin\, Adebrelimab and Bevacizumab in the Treatment o
 f TNBC-BM.\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07638852
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622771-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07622771)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Radiotherapy Combine
 d With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cance
 r: A Prospective\, Randomized\, Phase II Clinical Trial\nEstimated primary
  completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07622771
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06737913-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06737913)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: HAI or IV of Adebrelimab\, Combi
 ned With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocel
 lular Carcinoma\nEstimated primary completion: 30 June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06737913
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07033143-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07033143)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Evaluation of the Efficacy and S
 afety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and II
 IC Gastric Cancer\nEstimated primary completion: July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07033143
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241793-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07241793)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Phase II Study of Trastuzumab Re
 zetecan or in Combination With Adebrelimab in HER2-Expressing Locally Adva
 nced or Metastatic Urothelial Carcinoma (la/mUC)\nEstimated primary comple
 tion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07241793
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595172-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07595172)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: NALIRIFOX+Adebrelimab+PULSAR f
 or Advanced Pancreatic Cancer\nEstimated primary completion: August 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07595172
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381543-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07381543)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus
  CRT or CRT Alone\nEstimated primary completion: August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07381543
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773156-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06773156)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adjuvan
 t Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Ce
 ll Lung Cancer\nEstimated primary completion: 1 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06773156
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731828-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07731828)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant Short-course Hypofra
 ctionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Local
 ly Advanced Cervical Cancer: A Single-arm Phase II Trial\nEstimated primar
 y completion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07731828
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780721-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07780721)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Study of Adebrelimab Combined Wi
 th Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Ca
 ncer\nEstimated primary completion: 1 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07780721
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736612-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07736612)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Pan-RAS Inhibitor in Combina
 tion With Anti-Tumor Therapy in Participants With Advanced Pancreatic Canc
 er\nEstimated primary completion: 30 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07736612
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457346-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07457346)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Study Testing Emactinib Sulfat
 e With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and
  Neck Cancer\nEstimated primary completion: 30 August 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07457346
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839560-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06839560)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Evaluating the Efficacy and Safe
 ty of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy 
 and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Nega
 tive Breast Cancer With Brain Metastasis\nEstimated primary completion: 10
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adeb
 relimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06839560
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771609-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06771609)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Phase II Clinical Trial of PD-L1
  in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) M
 etronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-ne
 gative Breast Cancer.\nEstimated primary completion: 10 September 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06771609
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892625-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT07892625)
DESCRIPTION:Adebrelimab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Phase
  I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab
  in Patients With ES-SCLC\nEstimated primary completion: 15 September 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07892625
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357532-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07357532)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Explora
 tion of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCL
 C Guided by MRD\nEstimated primary completion: 26 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07357532
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06335355-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06335355)
DESCRIPTION:Adebrelimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemot
 herapy in Advanced or Metastatic NSCLC Patients\nEstimated primary complet
 ion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06335355
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317778-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07317778)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Chemotherapy With or Without Ade
 brelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Bre
 ast Cancer\nEstimated primary completion: 15 October 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07317778
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796113-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07796113)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab With Famitinib and C
 hemotherapy as Neoadjuvant Therapy for ESCC\nEstimated primary completion:
  30 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ade
 brelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07796113
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905950-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07905950)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Exploratory Study of Short-Cours
 e Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Orga
 n Preservation in Locally Advanced Rectal Cancer\nEstimated primary comple
 tion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07905950
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912957-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07912957)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Neoadjuvant SHR-A1811 ± Adebrel
 imab in GC/GEJ\nEstimated primary completion: 31 October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07912957
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284992-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07284992)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: SCRT VS LCRT Followed by PD-L1 I
 nhibitor Plus CAPEOX as TNT in Patients With LARC\nEstimated primary compl
 etion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07284992
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06842472-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06842472)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: PD-L1 Inhibitor + RT ± Ursodeox
 ycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06842472
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268040-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07268040)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Trial of SHR-7787 Injection Co
 mbined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07268040
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567326-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07567326)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resecta
 ble NSCLC\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07567326
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865611-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07865611)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Response-Guided Bladder Preserva
 tion With Trastuzumab Rezetecan\, Adebrelimab\, and Concurrent Bladder Rad
 iotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07865611
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07798947-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07798947)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase
  II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection 
 in Patients With LS-SCLC\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07798947
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569679-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07569679)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Alternating HAIC and Systemic Ch
 emotherapy With or Without Adebrelimab and Apatinib for Unresectable Bilia
 ry Tract Cancer\nEstimated primary completion: 30 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07569679
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963502-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06963502)
DESCRIPTION:Adebrelimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Pa
 tients With Advanced Solid Tumors\nEstimated primary completion: 31 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0696
 3502
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886047-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT07886047)
DESCRIPTION:Adebrelimab\, phase 1\, Small Cell Lung Cancer.\nStudy: Propran
 olol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemothera
 py in Small Cell Lung Cancer\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07886047
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806058-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07806058)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: An Open-Label\, Multicenter\, 
 Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Thera
 py in Participants With Solid Tumors\nEstimated primary completion: 31 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7806058
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06181032-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Adebrelimab: Phase 1 readout est. (NCT06181032)
DESCRIPTION:Adebrelimab\, phase 1.\nStudy: A Study of Adebrelimab in Combin
 ation With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancie
 s\nEstimated primary completion: 23 February 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06181032
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924332-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07924332)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Retlirafusp Alfa or Adebrelimab 
 Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Ga
 stroesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 M
 arch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 924332
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811375-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07811375)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Perioperative Adebrelimab for Lo
 cally Advanced Cervical Cancer\nEstimated primary completion: 31 March 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07811375
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771154-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06771154)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Plus Carboplatin/Pac
 litaxel Followed by Adebelizumab with or Without Apatinib in the Treatment
  of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicent
 er\, Randomized\, Controlled\, Open-Label Clinical Trial\nEstimated primar
 y completion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06771154
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Phase IB/II Clinical Study o
 f SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patie
 nts With Advanced Solid Tumors\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06474455
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559786-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290717
DTEND;VALUE=DATE:20290718
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07559786)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Multi
 center\, Open-label\, Randomized\, Prospective Clinical Study of Adebrelim
 ab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC
 ) Without Progression After Concurrent Chemoradiotherapy\nEstimated primar
 y completion: 17 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07559786
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Establishment of Precision Targe
 ted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecula
 r Subtyping\nEstimated primary completion: 1 August 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543783-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07543783)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Efficacy and Safety of Low-dose 
 Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization
  Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-l
 ine Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phas
 e 2 Trial\nEstimated primary completion: 31 August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07543783
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827053-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07827053)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Clinical Study of Radiotherapy C
 ombined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally A
 dvanced Pancreatic Cancer\nEstimated primary completion: 1 September 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07827053
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836543-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07836543)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tra
 stuzumab Rezetecan and Adebrelimab\, Alone or in Combination\, After Chemo
 radiotherapy for HER2-Altered Unresectable Stage III Lung Cancer\nEstimate
 d primary completion: December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07836543
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229625-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07229625)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Study of SHR-8068 in
  Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus 
 Durvalumab in Combination With Platinum-Containing Chemotherapy as First-l
 ine Treatment for Advanced Biliary Tract Cancer (BTC)\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07229625
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522151-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07522151)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: Clinical Study of Adebrelimab Th
 erapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal
  Junction Cancer\nEstimated primary completion: December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07522151
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890636-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07890636)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC\nEstimated pr
 imary completion: 1 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07890636
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238569-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07238569)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: Phase III Trial of EBV-DNA-Guide
 d Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma\nEstimated 
 primary completion: 1 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07238569
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615283-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07615283)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Adebrelimab Combined With SHR2
 554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma\nEstimated primary 
 completion: 29 May 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07615283
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822542-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07822542)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or 
 Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Thera
 py in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer\n
 Estimated primary completion: 31 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07822542
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266025-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07266025)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: Adebrelimab Combined With Induct
 ion Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite 
 Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Ju
 nction Adenocarcinoma：A Randomized\, Non-comparative Phase 2 Study\nEsti
 mated primary completion: 30 June 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07266025
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684040-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07684040)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Study of Combination Therapy i
 n Patients With Resectable Liver Cancer\nEstimated primary completion: 1 J
 uly 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 84040
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07118527-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07118527)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Study of SHR-A1811 i
 n Combination With Chemotherapy and Adebrelimab in Previously Untreated Pa
 tients With Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated
  primary completion: October 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07118527
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07900789)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: HRS-4642 Combined With Antitumor
  Agents for the Treatment of Perioperative Pancreatic Cancer\nEstimated pr
 imary completion: 30 November 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239596-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07239596)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Phase Ib/II Clinical Study of 
 SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell
  Carcinom\nEstimated primary completion: December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07239596
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679360-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07679360)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Study of Trastuzumab Rezetecan
  in Combination With Adebrelimab Versus Investigator's Choice of Therapy i
 n Subjects With Residual Triple Negative Breast Cancer\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07679360
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overex
 pressing Non-squamous Non-small Cell Lung Cancer\nEstimated primary comple
 tion: February 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07896005
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861777-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06861777)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: Total Neoadjuvant Therapy Comb
 ined With Adebrelimab in Locally Advanced Resectable ESCC\nEstimated prima
 ry completion: May 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06861777
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691762-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07691762)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Study of TACE in Combination W
 ith SHR-8068\, Adebrelimab\, and Bevacizumab Versus TACE in Participants W
 ith Incurable Hepatocellular Carcinoma\nEstimated primary completion: Sept
 ember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7691762
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071714-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07071714)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Phase II Study of SHR-8068 Inj
 ection in Combination With Anti-tumor Therapies in Colorectal Cancer\nEsti
 mated primary completion: October 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07071714
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879145-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06879145)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: Clinical Study on the Treatmen
 t of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR
 -1316)\nEstimated primary completion: December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06879145
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417554-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06417554)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Trial of SHR-A2102 With or W
 ithout Antitumor Therapy in Advanced Solid Tumors\nEstimated primary compl
 etion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06417554
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454720-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT07454720)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: A Clinical Study of Adebrelima
 b in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Ther
 apy for Locally Advanced Rectal Cancer\nEstimated primary completion: Nove
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 454720
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895238-2166@assetmemo.bio
DTSTAMP:20261121T004006Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07895238)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therap
 y in Patients With Resectable NSCLC\nEstimated primary completion: 31 Dece
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 895238
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
